Innovative Insights into Traumatic Brain Injuries: Biomarkers and New Pharmacological Targets
- PMID: 38397046
- PMCID: PMC10889179
- DOI: 10.3390/ijms25042372
Innovative Insights into Traumatic Brain Injuries: Biomarkers and New Pharmacological Targets
Abstract
A traumatic brain injury (TBI) is a major health issue affecting many people across the world, causing significant morbidity and mortality. TBIs often have long-lasting effects, disrupting daily life and functionality. They cause two types of damage to the brain: primary and secondary. Secondary damage is particularly critical as it involves complex processes unfolding after the initial injury. These processes can lead to cell damage and death in the brain. Understanding how these processes damage the brain is crucial for finding new treatments. This review examines a wide range of literature from 2021 to 2023, focusing on biomarkers and molecular mechanisms in TBIs to pinpoint therapeutic advancements. Baseline levels of biomarkers, including neurofilament light chain (NF-L), ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1), Tau, and glial fibrillary acidic protein (GFAP) in TBI, have demonstrated prognostic value for cognitive outcomes, laying the groundwork for personalized treatment strategies. In terms of pharmacological progress, the most promising approaches currently target neuroinflammation, oxidative stress, and apoptotic mechanisms. Agents that can modulate these pathways offer the potential to reduce a TBI's impact and aid in neurological rehabilitation. Future research is poised to refine these therapeutic approaches, potentially revolutionizing TBI treatment.
Keywords: molecular mechanisms; neuroprotection; physiological responses; regenerative medicine; rehabilitation; traumatic brain injury.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10889179/bin/ijms-25-02372-g001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10889179/bin/ijms-25-02372-g002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10889179/bin/ijms-25-02372-g003.gif)
Similar articles
-
The game changer: UCH-L1 and GFAP-based blood test as the first marketed in vitro diagnostic test for mild traumatic brain injury.Expert Rev Mol Diagn. 2024 Jan-Feb;24(1-2):67-77. doi: 10.1080/14737159.2024.2306876. Epub 2024 Jan 31. Expert Rev Mol Diagn. 2024. PMID: 38275158 Review.
-
Biomedical research brings mTBI biomarkers a step closer to the bedside - implementation in clinical practice.Gen Physiol Biophys. 2023 Jul;42(4):323-338. doi: 10.4149/gpb_2023013. Gen Physiol Biophys. 2023. PMID: 37449317 Review.
-
Serum Tau, Neurofilament Light Chain, Glial Fibrillary Acidic Protein, and Ubiquitin Carboxyl-Terminal Hydrolase L1 Are Associated with the Chronic Deterioration of Neurobehavioral Symptoms after Traumatic Brain Injury.J Neurotrauma. 2023 Mar;40(5-6):482-492. doi: 10.1089/neu.2022.0249. Epub 2022 Oct 18. J Neurotrauma. 2023. PMID: 36170576
-
Prognostic value of day-of-injury plasma GFAP and UCH-L1 concentrations for predicting functional recovery after traumatic brain injury in patients from the US TRACK-TBI cohort: an observational cohort study.Lancet Neurol. 2022 Sep;21(9):803-813. doi: 10.1016/S1474-4422(22)00256-3. Lancet Neurol. 2022. PMID: 35963263 Free PMC article.
-
The Levels of Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase-L1 During the First Week After a Traumatic Brain Injury: Correlations With Clinical and Imaging Findings.Neurosurgery. 2016 Sep;79(3):456-64. doi: 10.1227/NEU.0000000000001226. Neurosurgery. 2016. PMID: 26963330
References
-
- Wang K., Cui D., Gao L. Traumatic brain injury: A review of characteristics, molecular basis and management. Front. Biosci. Landmark. 2016;21:890–899. - PubMed
-
- Morrow S.E., Pearson M. Management Strategies for Severe Closed Head Injuries in Children. Elsevier; Amsterdam, The Netherlands: 2010. pp. 279–285. Seminars in Pediatric Surgery. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous